Recent Updates
Recently added Catalysts

ALKS 7290

Phase 2

Attention Deficit Disorder With Hyperactivity (ADHD) | Small molecule | Psychiatry |Alkermes plc|Last Updated: Aug 10, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment312

FDA Designations

No designations recorded

Clinical trial landscape

ALKS 7290 · 1 trial · 1 indication

Phase 2 1
NCT07755410A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)Attention Deficit Disorder With Hyperactivity (ADHD)
RECRUITING312 Analytics
PHASE2RECRUITING
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
Attention Deficit Disorder With Hyperactivity (ADHD)
NCT07755410312
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change from Baseline to Week 4 in Attention Deficit Disorder Investigator Symptom Rating Scale (AISRS) total score
Baseline to Week 4

Secondary Endpoints

Change from Baseline to Week 4 in Clinical Global Impression- Severity (CGI-S) scale score
Baseline to Week 4
Incidence of treatment-emergent adverse events
Up to 6 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Dose Level 1EXPERIMENTAL -
Dose Level 2EXPERIMENTAL -
Dose Level 3EXPERIMENTAL -
PlaceboPLACEBO_COMPARATORPlacebo capsule taken daily

Interventions

NameTypeDescription
ALKS 7290DRUGALKS 7290 tablets taken daily, orally, for 4 weeks
PlaceboDRUGPlacebo capsule taken daily
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Meets the Diagnostic and Statistical Manual of Mental Disorders -5 criteria for ADHD, as confirmed by the Mini-International Neuropsychiatric Interview (MINI) for ADHD Studies 7.0.2. * Is otherwise healthy as determined by medical evaluation, including medical history, physica...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWAug 11, 2026NCT07755410NEW_TRIAL: changed
LOWAug 11, 2026NCT07755410NEW_TRIAL: changed
LOWAug 11, 2026NCT07755410NEW_TRIAL: changed

Frequently asked questions about ALKS 7290

What is ALKS 7290 used for?

ALKS 7290 is an investigational small molecule being developed for the treatment of Attention Deficit Disorder With Hyperactivity (ADHD) in adults. It is currently in Phase 2 clinical development and has not been approved by the FDA.

Who makes ALKS 7290?

ALKS 7290 is being developed by Alkermes plc, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ALKS. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.

What phase is ALKS 7290 in?

ALKS 7290 is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. A Phase 2 trial is currently recruiting participants to evaluate its safety and efficacy compared with placebo in adults with ADHD.

What clinical trials is ALKS 7290 in?

ALKS 7290 is being studied in a Phase 2 clinical trial with the identifier NCT07755410. This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of ALKS 7290 in adult participants with ADHD. The trial is recruiting in the United States and aims to enroll 312 participants aged 18 years and older.

How does ALKS 7290 work?

The specific molecular target and mechanism of action for ALKS 7290 have not been disclosed. It is a small molecule being investigated for its potential to treat ADHD in adults, but its exact pharmacological action is not publicly detailed.